Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Endocrine journal

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1507/ENDOCRJ.49.323PMID 12201216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

  2006cited by this paper
• Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes.

  2000cited by this paper
• Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.

  2000cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Effect of troglitazone on the proinsulin level in patients with type 2 diabetes mellitus : A pilot study

  1999cited by this paper
• Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

  1998cited by this paper
• Effect of Metformin on Intact Proinsulin and des 31,32 Proinsulin Concentrations in Subjects with Non‐insulin‐dependent (Type 2) Diabetes Mellitus

  1996cited by this paper
• Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications

  1995cited by this paper
• Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats.

  1995cited by this paper
• Improved Beta Cell Function, with Reduction in Secretion of Intact and 32/33 Split Proinsulin, after Dietary Intervention in Subjects with Type 2 Diabetes Mellitus

  1994cited by this paper
• Effect of Sulphonylurea Therapy on Plasma Insulin, Intact and 32/33 Split Proinsulin in Subjects with Type 2 Diabetes Mellitus

  1994cited by this paper
• The biology of fish coccidia.

  1993cited by this paper
• Increased Proinsulin/Insulin Ratio in Pancreas Extracts of Hyperglycemic Rats

  1993cited by this paper
• The biosynthesis of the subtilisin-related proprotein convertase PC3, but no that of the PC2 convertase, is regulated by glucose in parallel to proinsulin biosynthesis in rat pancreatic islets.

  1993cited by this paper
• Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

  1992cited by this paper
• Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.

  1991cited by this paper
• Banting lecture 1990. Beta-cells in type II diabetes mellitus.

  1991cited by this paper
• β-cells in type II diabetes mellitus

  1991cited by this paper
• Effects of Dietary Treatment on Serum Insulin and Proinsulin Response in Newly Diagnosed NIDDM

  1989cited by this paper
• Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

  1987cited by this paper

• In Silico Hypothesis Testing in Drug Discovery: Using Quantitative Systems Pharmacology Modeling to Evaluate the Therapeutic Value of Proinsulin Conversion to Insulin Therapy for Type 2 Diabetes Mellitus

  2025cites this paper
• Relationship Between Patient-Health Coach Interactions and Changes in Markers of Glucose Homeostasis

  2018influential citation
• Combination Therapy «Metformin + Glimepiride» in Patients with Type 2 Diabetes Mellitus (Molecular Mechanisms for Optimization of the Rehabilitation Effect)

  2015cites this paper
• Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment.

  2014cites this paper
• Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS) — the effect of metformin treatment Proinsulina, adiponektyna i hsCRP u kobiet w wieku rozrodczym z zespołem policystycznych jajników (PCOS) — wpływ leczenia metforminą

  2014cites this paper
• Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes.

  2013cites this paper
• A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.

  2011cites this paper
• Elevated Intact Proinsulin Levels are Indicative of Beta-Cell Dysfunction, Insulin Resistance, and Cardiovascular Risk: Impact of the Antidiabetic Agent Pioglitazone

  2011cites this paper
• Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use

  2009cites this paper
• Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Pioglitazone attenuates fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells

  2008cites this paper
• Reduced postprandial proinsulinaemia and 32–33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone

  2008cites this paper
• Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

  2007cites this paper
• Choice of monotherapy in newly diagnosed Type 2 diabetic patients: clinical perspective of ADOPT

  2007cites this paper
• Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.

  2006cites this paper
• Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

  2005cites this paper
• Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome

  2005cites this paper
• Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin.

  2005cites this paper
• Proinsulin als Marker - wofür?

  2005cites this paper
• IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design

  2005cites this paper
• Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.

  2005cites this paper
• Potential Role of Oral Thiazolidinedione Therapy in Preserving β-Cell Function in Type 2 Diabetes Mellitus

  2005cites this paper
• Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.

  2005cites this paper
• Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control

  2005cites this paper
• Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes

  2005cites this paper
• The Relationship between BMI, Plasma Leptin, Insulin and Proinsulin Before and After Laparoscopic Adjustable Gastric Banding

  2005cites this paper
• [The place of thiazolidinediones in the treatment of type 2 diabetes].

  2004cites this paper
• Thiazolidinediones as PPAR Agonists

  2004cites this paper
• Place des thiazolidinediones dans le traitement du diabète de type 2

  2004cites this paper
• Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β

  2004cites this paper
• Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.

  2004cites this paper
• Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus

  2004cites this paper
• Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes.

  2004cites this paper
• Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta.

  2004cites this paper
• Trends in Management of Type 2 Diabetes: Role of Thiazolidinediones

  2003cites this paper
• Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.

  2003cites this paper
• Coronary artery disease and stroke in HIV-infected patients: prevention and pharmacological therapy.

  2003cites this paper